Results

Total Results: 1,653 records

Showing results for "described".

141. Disposition of Comments for Use of Natriuretic Peptide Measurement in the Management of Heart Failure (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/heart-failure-natriuretic-peptide_disposition-comments.pdf
     November 20, 2013 - The Methods are well described in the text of the report. … Corrected in report Rev 3 results Page 249 – several of the studies are described as a RCTs. … We used the definition of HF as described by each author for his/her study. … The clinical context has been described as recommended in current clinical practice guidelines. … The algorithms for use of NP in practice are described in both the Canadian and European guideline.

142. Untitled (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/mental-health-children_research-protocol.pdf
     December 11, 2015 - , skills building); and (4) strategies that use a multipronged approach with any of the previously described … The appropriateness of those studies will be determined using the methods described above. … As described above, all results will be tracked in an EndNote database. … For systematic reviews, we will use the five-step process described in the AHRQ Methods Guide37 to assess … This information will contextualize the published data and inform additional analysis described

143. Ch 8-User-Guide-To-Ocer 130129 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/ch_8-user-guide-to-ocer_130129.pdf
     October 01, 2013 - The observational research designs that often require primary data collection are described here. … contained in claims data by reviewing the paper record to see if the diagnosis or procedure was described … This is described in more detail below. … Wu et al. described several strategies that could be employed to increase the availability of PROs … Another strategy, as described by Wu et al., is the required participation of all Medicare managed

144. Disposition of Comments Report for Local Therapies for Unresectable Primary Hepatocellular Carcinoma (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/liver-cancer-therapy_disposition-comments.pdf
     May 24, 2013 - Limitations are adequately described. … applicable literature; the finding is clearly stated, however, and limitations of the review are described … Technical Expert #2 Discussion/ Conclusion Future research needs are relatively well described in … Characteristics of the studies are clearly described, although inclusion of patient populations (tumor … Technical Expert #2 Results The characteristics of the 44 studies included are well described, and key

145. Evidence-based Practice Center Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/prostate-cancer-surveillance_research-protocol.pdf
     May 19, 2011 - the review. 3 For the assessment of randomized and nonrandomized studies, we will adapt methods as described … intention-to-treat analysis, report of the study dropout rate, and the extent to which valid primary outcomes were described … strength of evidence for each of the outcomes addressed in the specific KQs by following guidelines described

146. Disposition of Comments for PCA3 Testing for the Diagnosis and Management of Prostate Cancer (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/prostate-cancer-test_disposition-comments.pdf
     April 01, 2013 - Individual Study Quality Assessment methods are also well described. … The strengths and weaknesses of the review were well described. … Study characteristics are clearly described. … PR # 6 Results Studies are clearly described. Comment acknowledged. … The methodology was exhaustingly described.

147. Assessing Applicability (ppt file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/assessing-applicability.ppt
     January 01, 2009 - In the intervention column, the type of surgical procedure is described. … In the comparator column, the comparator is described, and then the extent of use of other medications … Important limitations of the applicability of the evidence should be described within each summary conclusion … Finally, we learned that important limitations of the applicability of the evidence should be described

148. labor-dystocia-protocol-amended-160728 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/labor-dystocia_research-protocol.pdf
     July 28, 2016 - Data necessary for assessing quality and applicability, as described in the Methods Guide,20 will also … Disagreements will be resolved as described above, either by consensus or by obtaining a third reviewer … The strength of evidence will be assessed using the approach described in AHRQ’s Methods Guide.20,26 … Key aspects of previous reviews to be described include number and types of studies included, strength … Assessing Applicability We will assess applicability across our key questions using the method described

149. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/stem-cell-children_research-protocol.pdf
     November 01, 2010 - on above criteria: The rating of intervention studies encompasses the three quality categories described … • Were inclusion/exclusion criteria clearly described? … • Were baseline prognostic characteristics clearly described and groups shown to be comparable? … study population • Well-described intervention • Use of validated outcome measures • Appropriate … statistical analyses • Well-described results • Discussion and conclusion supported by data • Funding

150. Disparities-Quality-Improvement Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/disparities-quality-improvement_executive.pdf
     August 01, 2012 - conditions and demographic attributes.3,4 Disparities that occur between identified populations are described … An intervention could also be described as a strategy aimed at reducing the quality gap (the difference … Broadly, we sought studies that described a QI intervention and measured potential changes in the inequity … The collaborative care models described in this report were all associated with improvements in mental … The usual-care comparators described in these studies may not be applicable to other settings and regions

151. Disposition of Comments for Child Exposure to Trauma: Comparative Effectiveness of Interventions Addressing Maltreatment (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/trauma-interventions-maltreatment-child_disposition-comments.pdf
     April 15, 2013 - ) was not included in KQ3 because the theoretical orientation of the comparator was not clearly described … Research and Substantive Gaps summarizes limitation of the evidence-based studies described but may … No action needed Peer Reviewer #5 Results The studies are very clearly and thoroughly described. … The characteristics of the studies are clearly described particularly in association with the figures … Limitations are adequately described. The authors did not omit any important literature.

152. Omega-3 Fatty Acids and Cardiovascular Disease: An Updated Systematic Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/fatty-acids-cardiovascular-disease_disposition-comments.pdf
     August 12, 2016 - The limitations of the current evidence are well described but it would be helpful for the authors … The outcomes MACE and CVD have been clarified, made more distinct from each other, and described … Thank you Peer Reviewer #2 Methods The methods described are appropriate and consistent with those … We categorized outcomes bases on how they were described and reported in the studies. … of detail presented is impressive and extremely useful. that implies that the studies are clearly described

153. Integrating Bodies of Evidence: Existing Systematic Reviews and Primary Studies (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/integrating-evidence_methods.pdf
     February 01, 2015 - In the Results section, we present the themes by the three general topics described above. … The importance of transparency was emphasized by all KIs; the RoB tool should have been described in … Some organizations reported using the existing grading of a prior review if the assessment is described … As described above, recent EPC work has addressed when to update a review12-14 and an EPC Workgroup … The risk of bias assessments from the existing systematic review may be used when the review described

154. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/psoriasis-chronic_research-protocol.pdf
     January 10, 2012 - † Plaque psoriasis development stage is described by: Phase (number of studies): status (if applicable … † Plaque psoriasis development stage is described by: Phase (number of studies): status (if applicable … The same inclusion/exclusion criteria previously described will be applied to packets that are received … The same inclusion/exclusion criteria previously described will be applied to packets that … The same inclusion/exclusion criteria previously described will be applied to packets that are

155. Microsoft Word - 3-DKE274__ACEI-ARB-DRI__Comments_Disposition_Table-21_Jan_2011 cyk _2_.docx (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/ace-inhibitor-arb-update_disposition-comments.pdf
     October 07, 2011 - of these products in any manner other than as approved by the Food and Drug Administration and as described … Methods Pgs. 31 & 32: Analytic framework is described nicely. Thank you. … As described below we have now clarified the forest plot labeling. … These are described in the full prescribing information for ZESTRIL and below. … The extremely rare events described by the reviewer all represent putative interactions that are beyond

156. Study Objectives and Questions for Observational Comparative Effectiveness Research
     effectivehealthcare.ahrq.gov/sites/default/files/study-objectives-and-questions-chapter-1.pptx
     January 01, 2013 - frame for regulatory, ethical, or other reasons, this interval should be expressed to researchers and described … The principles described in this chapter are intended to strengthen the writing of research protocols

157. Hypertension-Pulmonary-Arterial Research-Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/hypertension-pulmonary-arterial_research-protocol.pdf
     January 30, 2013 - suggest advanced disease.4 The diagnosis of PAH requires a multifaceted approach by the clinician as described … Data necessary for assessing quality and applicability, as described in the Methods Guide,16 will also … We will evaluate the quality of individual studies by using the approach described in the Methods Guide … Results will be described for individual domains. … The strength of evidence will be assessed by using the approach described in the Methods Guide.19 In

158. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/lung-cancer-nonsurgical-therapies_research-protocol.pdf
     February 22, 2012 - Serious complications have been described with endobronchial BT, including massive hemoptysis, tracheoesophageal … ○ Were inclusion/exclusion criteria clearly described? … ○ Were baseline prognostic characteristics clearly described and groups shown to be comparable? … study population ○ Well-described intervention ○ Use of validated outcome measures ○ Appropriate … statistical analyses ○ Well-described results ○ Discussion and conclusion supported by data ○

159. Disposition of Comments for CER 153 Non-Muscle-Invasive Bladder Cancer (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/bladder-cancer-non-muscle-invasive_disposition-comments.pdf
     October 27, 2015 - MMC, noting that no trial or direct comparison has been made to MMC using the optimized regimen described … EORTC trial 30962 comparing one year vs. 3 year The Oddens trial was included in our review; as described … Page 124 line 21-26 – see comment 7 above The Oddens trial was included in our review; as described … Results The amount of detail in the results is appropriate, and study characteristics are clearly described … major findings are clearly stated and limitations of the review (as well as included studies) are described

160. Disposition of Comments for Chronic Urinary Retention: Comparative Effectiveness and Harms of Treatments (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/chronic-urinary-retention_disposition-comments.pdf
     September 15, 2014 - detail presented in the results section is appropriate - Characteristics of the studies are well described … Characteristics of the studes are clearly described. … The limitations are described adequately. … These are described in the more detailed appendix H tables. … The characteristics of the studies are clearly outlined and described.